BioStratum raises $20 million

BioStratum ( Research Triangle Park, N.C.) raised $20 million in a private round. Investors included HealthCap; MP Bio; Equity Resources Group; and BankInvest. BioStratum is in Phase II testing of its Pyridorin, an inhibitor of non-enzymatic glycoxidation leading to advanced glycation end-product (AGE) formation, to treat diabetic kidney disease. ...